ATE378015T1

System for use in treating a patient with any drug to optimize therapy and prevent an adverse drug response

Abstract

A method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.

Term

Term ended

Projected expiry passed 6 July 2020, 6.2 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

58 members in 16 offices

This recordMember, by publication datePriority claim6 more offices are in the list below

Priority claims1

Priority claims
DocumentOfficeKindDate
34859299United States of AmericaA

Members58

Family members, oldest first
DocumentOfficeKind
CA2362429A1CanadaA1
WO0102050A2World Intellectual Property Organization (WIPO)A2
AU5919800AAustraliaA
US6267116B1United States of AmericaB1
US2001018919A1United States of AmericaA1
US2001020475A1United States of AmericaA1
CA2404517A1CanadaA1
WO0174084A2World Intellectual Property Organization (WIPO)A2
AU5121501AAustraliaA
US2001042551A1United States of AmericaA1
US2001050920A1United States of AmericaA1
NO20020043D0NorwayD0
NO20020056D0NorwayD0
NO20020056LNorwayL
WO0102050A3World Intellectual Property Organization (WIPO)A3
WO0174084A3World Intellectual Property Organization (WIPO)A3
WO0174084B1World Intellectual Property Organization (WIPO)B1
CA2419431A1CanadaA1
WO0219935A1World Intellectual Property Organization (WIPO)A1
AU8486801AAustraliaA
BR0012241ABrazilA
EP1191894A2European Patent Office (EPO)A2
KR20020036790ARepublic of KoreaA
MXPA01013306AMexicoA
CN1359276AChinaA
IL147201A0IsraelA0
IL147201D0IsraelD0
TR2001003831T2TürkiyeT2
TR200103831T2TürkiyeT2
WO02082972A2World Intellectual Property Organization (WIPO)A2
WO02082972A9World Intellectual Property Organization (WIPO)A9
EP1273174A2European Patent Office (EPO)A2
JP2003503165AJapanA
CA2455455A1CanadaA1
WO03011215A2World Intellectual Property Organization (WIPO)A2
AU2002322611A1AustraliaA1
WO02082972A3World Intellectual Property Organization (WIPO)A3
IL151950A0IsraelA0
IL151950D0IsraelD0
EP1311202A1European Patent Office (EPO)A1
US6575169B2United States of AmericaB2
US6581606B2United States of AmericaB2
US6581607B2United States of AmericaB2
WO03011215A3World Intellectual Property Organization (WIPO)A3
CA2401913A1CanadaA1
NZ521644ANew ZealandA
EP1191894A4European Patent Office (EPO)A4
CA2362429CCanadaC
AU2001251215B2AustraliaB2
US6942614B1United States of AmericaB1
US7100193B2United States of AmericaB2
EP1311202A4European Patent Office (EPO)A4
EP1191894B1European Patent Office (EPO)B1
AT378015TAustriaT
ATE378015T1This recordAustriaT1
DE60037116D1GermanyD1
DE60037116T2GermanyT2
CA2455455CCanadaC